BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wei Z, Zhao D, Zhang Y, Chen Y, Zhang S, Li Q, Zeng P, Li X, Zhang W, Duan Y, Han J, Yang X. Rosiglitazone ameliorates bile duct ligation-induced liver fibrosis by down-regulating NF-κB-TNF-α signaling pathway in a PPARγ-dependent manner. Biochem Biophys Res Commun 2019;519:854-60. [PMID: 31561855 DOI: 10.1016/j.bbrc.2019.09.084] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Niu Q, Wang T, Wang Z, Wang F, Huang D, Sun H, Liu H. Adipose-derived mesenchymal stem cell-secreted extracellular vesicles alleviate non-alcoholic fatty liver disease via delivering miR-223-3p. Adipocyte 2022;11:572-87. [PMID: 36093813 DOI: 10.1080/21623945.2022.2098583] [Reference Citation Analysis]
2 Zhao D, Xue C, Yang Y, Li J, Wang X, Chen Y, Zhang S, Chen Y, Duan Y, Yang X, Han J. Lack of Nogo-B expression ameliorates PPARγ deficiency-aggravated liver fibrosis by regulating TLR4-NF-κB-TNF-α axis and macrophage polarization. Biomedicine & Pharmacotherapy 2022;153:113444. [DOI: 10.1016/j.biopha.2022.113444] [Reference Citation Analysis]
3 Fu M, Yin W, Zhang W, Zhu Y, Ni H, Gong L. MicroRNA-15a inhibits hepatic stellate cell activation and proliferation via targeting SRY-box transcription factor 9. Bioengineered 2022;13:13011-20. [PMID: 35611752 DOI: 10.1080/21655979.2022.2068895] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 He Q, Chen B, Wang G, Zhou D, Zeng H, Li X, Song Y, Yu X, Liang W, Chen H, Liu X, Wu Q, Wu L, Zhang L, Li H, Hu X, Zhou W. Co-Crystal of Rosiglitazone With Berberine Ameliorates Hyperglycemia and Insulin Resistance Through the PI3K/AKT/TXNIP Pathway In Vivo and In Vitro. Front Pharmacol 2022;13:842879. [PMID: 35571083 DOI: 10.3389/fphar.2022.842879] [Reference Citation Analysis]
5 Chen Q, Bao L, Lv L, Xie F, Zhou X, Zhang H, Zhang G. Schisandrin B regulates macrophage polarization and alleviates liver fibrosis via activation of PPARγ. Ann Transl Med 2021;9:1500. [PMID: 34805362 DOI: 10.21037/atm-21-4602] [Reference Citation Analysis]
6 Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y, Yao Y, Ye T. Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy. Front Cell Dev Biol 2021;9:730176. [PMID: 34621747 DOI: 10.3389/fcell.2021.730176] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
7 Monroy-Ramirez HC, Galicia-Moreno M, Sandoval-Rodriguez A, Meza-Rios A, Santos A, Armendariz-Borunda J. PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases. Int J Mol Sci 2021;22:8298. [PMID: 34361064 DOI: 10.3390/ijms22158298] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
8 Song YC, Lee SE, Jin Y, Park HW, Chun KH, Lee HW. Classifying the Linkage between Adipose Tissue Inflammation and Tumor Growth through Cancer-Associated Adipocytes. Mol Cells 2020;43:763-73. [PMID: 32759466 DOI: 10.14348/molcells.2020.0118] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Li J, Guo C, Wu J. The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis. Drug Des Devel Ther 2021;15:2619-28. [PMID: 34168433 DOI: 10.2147/DDDT.S310163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Esmail MM, Saeed NM, Michel HE, El-Naga RN. The ameliorative effect of niclosamide on bile duct ligation induced liver fibrosis via suppression of NOTCH and Wnt pathways. Toxicol Lett 2021;347:23-35. [PMID: 33961984 DOI: 10.1016/j.toxlet.2021.04.018] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Zhu Y, Qiao M, Yang J, Hu J. Elucidating the Mechanisms of Hugan Buzure Granule in the Treatment of Liver Fibrosis via Network Pharmacology. Evidence-Based Complementary and Alternative Medicine 2020;2020:1-11. [DOI: 10.1155/2020/8385706] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells 2020;9:E1638. [PMID: 32650421 DOI: 10.3390/cells9071638] [Cited by in Crossref: 16] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
13 Chhimwal J, Sharma S, Kulurkar P, Patial V. Crocin attenuates CCl4-induced liver fibrosis via PPAR-γ mediated modulation of inflammation and fibrogenesis in rats. Hum Exp Toxicol 2020;39:1639-49. [PMID: 32633567 DOI: 10.1177/0960327120937048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
14 Li S, Shi M, Wan Y, Wang Y, Zhu M, Wang B, Zhan Y, Ran B, Wu C. Inflammasome/NF-κB translocation inhibition via PPARγ agonist mitigates inorganic mercury induced nephrotoxicity. Ecotoxicol Environ Saf 2020;201:110801. [PMID: 32502906 DOI: 10.1016/j.ecoenv.2020.110801] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
15 Wang Y, Nakajima T, Gonzalez FJ, Tanaka N. PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice. Int J Mol Sci 2020;21:E2061. [PMID: 32192216 DOI: 10.3390/ijms21062061] [Cited by in Crossref: 42] [Cited by in F6Publishing: 105] [Article Influence: 21.0] [Reference Citation Analysis]